Explorer Study: an ambitious clinical trial

News & Event

Explorer Study: an ambitious clinical trial

Explorer: an ambitious study and a rigorous methodology to assess the efficacy of a dressing in the treatment of diabetic foot wounds.LOGO EXPLORER


Foot ulcers are one of the most common complications of diabetes. Worldwide 15% of diabetic patients will suffer from a foot wound at least once in their lifetime(1). Urgo Medical hopes to demonstrate the efficacy of UrgoStart® Contact compared to a neutral dressing in the local treatment of these wounds. UrgoStart® Contact is a TLC-NOSF (Nano-Oligo-Saccharide Factor) dressing shown in previous studies to be capable of restoring the biochemical balance of wounds and promoting healing. Explorer is a randomised, controlled, double-blind trial versus a neutral dressing; it complies with both European and American methodologies. The trial is being coordinated by Doctor Jacques Martini, from the Department of Endocrinology and Diabetology at Rangueil Hospital in Toulouse. 68 investigator centres are involved in the trial in Europe; 238 patients will be monitored over the course of a 20-week treatment period and a 12-week follow-up period. The primary endpoint observed is the complete healing rate at the end of a 20-week treatment period.


(1) International Diabetes Federation – Diabetes Atlas – 2012 edition and WHO

Last update : August 14, 2020